PG 931 acetate NEW
Price | $416 | $936 | $1270 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-11 |
Product Details
Product Name: PG 931 acetate | Purity: 98.74% |
Supply Ability: 10g | Release date: 2024/11/11 |
Product Introduction
Bioactivity
名稱 | PG 931 acetate |
描述 | PG 931 acetate is a potent agonist of melanocortin 4 (MC4) receptors. |
存儲條件 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關鍵字 | PG 931 acetate | 667430-81-1 Free base | 667430-81-1 | PG-931 Acetate | PG931 Acetate | PG 931 Acetate |
相關產品 | MCH(human, mouse, rat) | MCHR1 antagonist 2 | ATC 0175 hydrochloride | SNAP 94847 | Melanin Concentrating Hormone, salmon acetate | Neuropeptide EI, rat acetate | TC-MCH 7c | SNAP 94847 hydrochloride | [Ala17]-MCH acetate |
相關庫 | 經典已知活性庫 | 膜蛋白靶向化合物庫 | 多肽分子庫 | 已知活性化合物庫 | GPCR靶點分子庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$2180.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$150.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-04-22 | |
$35.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-13 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY